Managing type 1 diabetes requires a careful balance of insulin therapy, blood sugar monitoring, lifestyle choices, and regular medical oversight, but with the right tools and support, people living with this autoimmune condition can lead full and healthy lives.

What You Need to Know About Treating Type 1 Diabetes

When someone receives a diagnosis of type 1 diabetes, their body has stopped making insulin—a hormone essential for turning food into energy. This happens because the immune system mistakenly attacks the cells in the pancreas that produce insulin, known as beta cells. Without insulin, glucose builds up in the blood instead of entering cells, leading to dangerously high blood sugar levels that can cause serious health problems if left untreated.^[1][2]

The main goal of treatment is to replace the insulin the body can no longer make on its own. This involves taking insulin every day—either through injections or an insulin pump—to keep blood sugar levels within a healthy range. Treatment also includes regularly checking blood sugar levels, learning to match insulin doses with food and activity, and working closely with healthcare providers to prevent both short-term and long-term complications.^[3][8]

Treatment plans are highly individualized. What works for one person may not work for another, because factors like age, activity level, eating habits, and personal health goals all play a role. The American Diabetes Association recommends that most non-pregnant adults aim for an A1C level—a measure of average blood sugar over the past two to three months—of less than 7 percent. However, these targets can be adjusted based on individual circumstances, such as the risk of experiencing dangerously low blood sugar episodes known as hypoglycemia or hypos.^[11][16]

Beyond insulin, successful management involves education and support. People with type 1 diabetes benefit from courses that teach them how to count carbohydrates, adjust insulin doses, recognize warning signs of high or low blood sugar, and manage the condition during illness or other challenging situations. Family members, friends, and healthcare teams all play important roles in providing both practical and emotional support.^[5][19]

Standard Treatment Approaches

The foundation of type 1 diabetes treatment is insulin therapy. Because the body no longer produces this hormone, people with the condition must take it every day to survive. There are several types of insulin available, each with different speeds and durations of action. Most treatment plans combine rapid-acting insulin taken at mealtimes with long-acting basal insulin that works throughout the day and night to maintain steady blood sugar levels between meals and during sleep.^[12][14]

Insulin types include rapid-acting formulas that start working within 15 minutes and are taken just before or with meals, and long-acting versions that provide background coverage for up to 24 hours or more. Some people use intermediate-acting insulin as well. These different types are often used together in what’s called a basal-bolus regimen, which mimics the body’s natural insulin pattern more closely than older approaches.^[12]

Insulin can be delivered in several ways. Many people use insulin pens, which are convenient, portable devices that allow for precise dosing. Others prefer traditional syringes. For those seeking more flexibility and tighter control, insulin pumps offer an alternative. These small computerized devices attach to the body and deliver tiny amounts of insulin continuously throughout the day, with extra doses given at mealtimes. Pumps can reduce the number of injections needed and help achieve more stable blood sugar levels.^[14][19]

More recently, hybrid closed-loop systems have become available in some countries through national health services. These advanced devices combine an insulin pump with a continuous glucose monitor that automatically adjusts insulin delivery based on real-time blood sugar readings. This technology can significantly reduce the burden of constantly calculating insulin doses and helps prevent dangerous swings in blood sugar levels, particularly during sleep.^[19]

Monitoring blood sugar is done through finger-prick tests using a blood glucose meter or, increasingly, through continuous glucose monitors (CGMs). These small sensors inserted under the skin measure glucose levels constantly and send readings to a display device or smartphone. CGMs reduce the need for frequent finger pricks and can alert users when blood sugar is heading too high or too low, allowing for quicker responses. Studies show that more frequent blood sugar monitoring is associated with better A1C levels and fewer complications.^[16][19]

Managing type 1 diabetes also requires learning about carbohydrates and how they affect blood sugar. Through carbohydrate counting, or carb counting, people learn to estimate the amount of carbohydrates in their meals and adjust their insulin doses accordingly. This skill allows for much greater flexibility in food choices while still maintaining good blood sugar control. Many healthcare systems offer structured education programs, such as DAFNE (Dose Adjustment for Normal Eating), that teach these skills in a supportive group setting.^[19][22]

Side effects of insulin therapy include the risk of hypoglycemia if too much is taken relative to food intake or physical activity. Symptoms of low blood sugar include feeling shaky, sweaty, hungry, confused, or dizzy. Mild episodes can be treated by consuming 15 to 20 grams of fast-acting carbohydrate, such as fruit juice or glucose tablets. Severe hypoglycemia, where a person becomes unconscious or unable to swallow, requires emergency treatment with injectable glucagon or emergency medical services.^[19][22]

Another potential concern is lipodystrophy, which involves changes in the fat tissue under the skin at injection sites. This can happen if insulin is injected repeatedly in the same spot. To prevent this, it’s important to rotate injection sites and use proper technique. Weight gain can also occur with intensive insulin therapy, which is why balanced nutrition and regular physical activity are important components of overall care.^[12]

Standard treatment also includes regular medical check-ups. People with type 1 diabetes should have their A1C levels checked every three to six months to see how well their blood sugar has been controlled over time. They also need annual or more frequent screenings for complications affecting the eyes, kidneys, feet, and cardiovascular system. Blood pressure and cholesterol management are important because diabetes increases the risk of heart disease and stroke.^[11][19]

Promising Therapies Being Tested in Clinical Trials

While insulin remains the cornerstone of type 1 diabetes management, researchers are actively investigating new approaches that could improve outcomes, reduce the burden of daily management, or even modify the course of the disease. Clinical trials are testing various strategies, from medications originally developed for type 2 diabetes to advanced cell-based therapies and immune system interventions.^[15]

One of the most significant recent developments is the approval of teplizumab, marketed as Tzield, by the U.S. Food and Drug Administration in November 2022. This represents the first disease-modifying therapy for type 1 diabetes. Teplizumab is a monoclonal antibody—a laboratory-made protein that targets specific cells in the immune system. It works by binding to immune cells and temporarily modifying their activity, which appears to slow down the autoimmune attack on insulin-producing beta cells.^[14]

Importantly, teplizumab is not for people who already have clinical type 1 diabetes. Instead, it is approved for individuals at high risk of developing the condition who are in the early stages before symptoms appear. Type 1 diabetes develops in stages over time, and people with certain autoantibodies in their blood are at very high risk of eventually developing full-blown disease. Clinical trials have shown that teplizumab can delay the onset of symptomatic type 1 diabetes by approximately two years in these at-risk individuals. This delay gives people more time without the need for daily insulin injections and glucose monitoring.^[14]

Other immune-modifying therapies are being studied to see if they can preserve remaining beta cell function in people newly diagnosed with type 1 diabetes or prevent the disease in high-risk individuals. These approaches aim to interrupt or slow down the autoimmune process without completely suppressing the entire immune system, which would leave people vulnerable to infections.^[5][15]

Another area of investigation involves medications already used for type 2 diabetes. Although type 1 and type 2 diabetes are different diseases, some treatments for type 2 have shown potential as add-on therapies for type 1. For example, pramlintide (an amylinomimetic agent) is approved as an adjunctive therapy for people with type 1 diabetes who take mealtime insulin but don’t achieve their blood sugar targets. Pramlintide is a synthetic version of amylin, a hormone normally produced alongside insulin. It helps slow stomach emptying, reduces appetite, and limits glucose spikes after meals. However, it requires additional injections and can increase the risk of hypoglycemia, so careful dose adjustment is needed.^[14][17]

Clinical trials have also explored drugs called GLP-1 receptor agonists (such as the active ingredients in medications like Ozempic and similar drugs) and SGLT inhibitors in people with type 1 diabetes. GLP-1 agonists work by enhancing the body’s natural incretin response, which stimulates insulin release and suppresses glucagon (a hormone that raises blood sugar). They can also promote weight loss and may have cardiovascular benefits. SGLT inhibitors work by causing the kidneys to remove excess glucose through urine. While neither class of drug is currently approved specifically for type 1 diabetes, research is ongoing to determine their safety and effectiveness as adjunctive treatments. Early studies suggest they may help with blood sugar control and weight management, but concerns about side effects—particularly a serious complication called diabetic ketoacidosis with SGLT inhibitors—mean these therapies require careful evaluation.^[14][15]

Cell replacement therapies represent another frontier in type 1 diabetes research. Because the disease is caused by loss of insulin-producing beta cells, restoring these cells could potentially cure diabetes. Pancreas transplantation has been performed for decades, usually in people who also need a kidney transplant due to diabetes-related kidney failure. A successful pancreas transplant can restore normal insulin production and eliminate the need for exogenous insulin. However, this approach is limited by the shortage of donor organs and the need for lifelong immunosuppressive drugs to prevent organ rejection. These medications carry their own risks, including increased susceptibility to infections and certain cancers.^[12][15]

Islet cell transplantation is a less invasive alternative to whole pancreas transplantation. In this procedure, insulin-producing islet cells are isolated from a donor pancreas and infused into the recipient’s liver through a minimally invasive procedure. Clinical studies have shown that islet transplantation can help people achieve better blood sugar control and, in some cases, become temporarily insulin-independent. However, like whole organ transplantation, this approach requires immunosuppression and is limited by donor availability. Many recipients eventually need to resume insulin therapy as the transplanted islets gradually fail.^[12][15]

To overcome the limitations of current cell replacement approaches, researchers are developing techniques to create insulin-producing cells from stem cells. Stem cells are special cells that can develop into many different cell types. Scientists have successfully created beta-like cells from stem cells in the laboratory, and early clinical trials are testing whether these cells can survive and function when transplanted into people with type 1 diabetes. Various strategies are being explored to protect these cells from immune attack without requiring systemic immunosuppression, including encapsulation devices that allow nutrients and insulin to pass through but block immune cells.^[15]

Another innovative area of research involves smart insulin systems. These are insulin molecules that have been chemically modified to respond to glucose levels in the blood. In theory, smart insulin would automatically release when blood sugar rises and stop releasing when it falls, mimicking the body’s natural insulin production much more closely than current insulins. While this technology is still in early experimental phases, it holds promise for dramatically reducing the risk of hypoglycemia and the burden of constant blood sugar monitoring and insulin dose calculations.^[12]

Artificial pancreas technology, also known as automated insulin delivery systems, represents a major step forward available now. In 2016, the FDA approved the first hybrid closed-loop system, which combines continuous glucose monitoring with an insulin pump that automatically adjusts basal insulin delivery. These systems still require users to announce meals and give bolus doses, but they handle much of the hour-to-hour insulin adjustment automatically. Newer systems with even more automation are in development and testing, with the long-term goal of creating a fully automated artificial pancreas that requires minimal user input.^[17]

Clinical trials for type 1 diabetes typically proceed through several phases. Phase I trials test safety and dosing in small groups of people. Phase II trials evaluate whether a treatment works and continue to assess safety in larger groups. Phase III trials compare the new treatment to standard care in even larger populations to confirm effectiveness and monitor side effects. Many trials are conducted at major medical centers in the United States, Europe, and other regions. Eligibility varies depending on the study but often includes factors like age, duration of diabetes, presence of residual insulin production, and A1C levels.^[5]

Most Common Treatment Methods

• Insulin Therapy
  • Rapid-acting insulin taken at mealtimes to cover food intake
  • Long-acting basal insulin for background coverage throughout the day and night
  • Insulin delivered via pens, syringes, or pumps
  • Hybrid closed-loop systems that combine continuous glucose monitoring with automated insulin delivery
• Blood Glucose Monitoring
  • Finger-prick tests using blood glucose meters
  • Continuous glucose monitors (CGMs) that measure sugar levels constantly
  • Recommended testing at least four to five times daily, or more during exercise, illness, or other situations
• Adjunctive Medications
  • Pramlintide (amylinomimetic) to limit glucose spikes after meals
  • Blood pressure medications (ACE inhibitors, ARBs) for cardiovascular protection
  • Statins and other lipid-lowering drugs to manage cholesterol
• Disease-Modifying Therapy
  • Teplizumab (Tzield) to delay onset of symptomatic type 1 diabetes in at-risk individuals
  • Other immune-modulating therapies under investigation to preserve beta cell function
• Cell Replacement Approaches
  • Whole pancreas transplantation, usually combined with kidney transplant
  • Islet cell transplantation infused into the liver
  • Stem cell-derived beta cells in early clinical trials
  • Encapsulation techniques to protect transplanted cells from immune attack
• Diabetes Education and Support
  • Structured courses like DAFNE teaching carbohydrate counting and insulin adjustment
  • Regular appointments with diabetes care teams including nurses, dietitians, and specialists
  • Mental health support to address depression, anxiety, and diabetes-related distress